RGPX · As filed with the SEC

Regenerex Pharma balance sheet, by fiscal year

The statement as Regenerex Pharma presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.

BALANCE SHEETS · USD

USDFY2024
Mar 31, 2025
FY2023
Mar 31, 2024
FY2023
Mar 31, 2023
FY2022
Mar 31, 2022
ASSETS
Cash and Cash Equivalents653,0253721,1352,640
Prepaid Expenses3502,540—5,256
Total Current Assets653,3752,9121,1357,896
Intangible Assets—1,3284,2037,426
Property, Plant and Equipment5,5996,0971,201—
Operating Lease Right-of-Use Asset604,262756,343——
Total Assets1,263,236766,6806,53915,322
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Accounts Payable197,673116,76075,14563,027
Other Non-Operating Current Liabilities——131,887131,687
Related party advances13,6523,690——
Accrued Compensation and Benefits842,620511,847221,192221,192
Other Current Liabilities88,26897,251125,78791,667
Short-Term Debt2,824,2322,400,000222,771152,880
Shareholder469,105475,050——
Other Affiliates306,103110,500——
Operating Lease Liability, Current181,894128,264——
Total Current Liabilities4,923,5473,843,362776,782660,453
Long-Term Debt—119,114314,704340,486
Notes payable to related parties, net of current portion——38,000—
Long-Term Debt—184,232——
Operating Lease Liability, Non-Current495,894681,798——
Total Liabilities5,419,4414,828,5061,129,4861,000,939
Stockholders’ Deficit
Total Stockholders' Equity281,071278,226277,113277,113
Additional Paid-In Capital3,705,6151,275,798671,963671,963
Retained Earnings(8,142,891)(5,615,850)(2,072,023)(1,934,693)
Total Equity(4,156,205)(4,061,826)(1,122,947)(985,617)
Total Liabilities and Equity1,263,236766,6806,53915,322

As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.